Machine learning approaches to predict Acetylcholinesterase inhibition and model applications
Award amount
$2,044,647Program and phase
SBIR · Phase IIAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- COLLABORATIONS PHARMACEUTICALS INC
- Proposal award date
- 2024-09-04
- Contract end date
- 2026-06-30
- UEI
- EFJCLL37KKH3
- Solicitation number
- PA23-230
- Topic code
- R
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Pyronaridine as an oral Treatment for Ebola
- Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease
- Preclinical development of a Nipah Virus inhibitor
- MegaTox for analyzing and visualizing data across different screening systems
- Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease
Research funding history
18 SBIR/STTR records share this UEI (2016–2025). Reported award amounts total $20,250,279. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services